Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
Prognosis for patients with refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Immune-based therapeutic treatments such as CD19 Chimeric Antigen Receptor (CAR) T cell therapies have dramatically changed the treatment landscape for R/R DLBCL leading to durable remissions in ~ 50...
Main Authors: | Suheil Albert Atallah-Yunes, Michael J. Robertson, Utpal P. Davé, Paola Ghione, Fabiana Perna |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.901365/full |
Similar Items
-
CAR T-Cell therapy for the management of mantle cell lymphoma
by: Zoufang Huang, et al.
Published: (2023-03-01) -
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
by: Maria Giraudo, et al.
Published: (2024-03-01) -
TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma
by: Kyung-Eun Noh, et al.
Published: (2021-08-01) -
A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models
by: Wing Keung Chan, et al.
Published: (2023-09-01) -
Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma
by: Colton Ladbury, et al.
Published: (2023-03-01)